From: High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection
Clinical characteristic | ANA-positive | ANA-negative | p-value |
---|---|---|---|
Systemic arterial hypertension | 8 (44.4%) | 24 (35.8%) | 0.1243Q |
Diabetes mellitus 2 | 2 (11.1%) | 13 (19.4%) | 0.5093E |
Hepatomegaly | 0 | 11 (16.4%) | 0.1100E |
Hepatic steatosis | 5 (31.2%) | 11 (17.2%) | 0.1278Q |
Cirrhosis | 6 (33.3%) | 9 (12.7%) | 0.0708Q |
Necroinflammatory activityG | |||
A0 | 1 (8.33%) | 4 (7.55%) | 0.6820 |
A1 | 7 (58.33%) | 27 (50.94%) | |
A2 | 4 (33.3%) | 18 (33.96%) | |
A3 | 0 | 4 (7.55%) | |
Degree of fibrosisG | |||
F0 | 0 | 4 (7.55%) | 0.0770 |
F1 | 2 (16.67%) | 20 (37.73%) | |
F2 | 3 (25%) | 16 (30.18%) | |
F3 | 4 (33.3%) | 12 (22.64%) | |
F4 | 3 (25%) | 1 (1.89%) |